Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug;42(2):202-12.
doi: 10.1016/j.jpainsymman.2010.10.257. Epub 2011 Mar 12.

Fatigue, dyspnea, and cough comprise a persistent symptom cluster up to five years after diagnosis with lung cancer

Affiliations

Fatigue, dyspnea, and cough comprise a persistent symptom cluster up to five years after diagnosis with lung cancer

Andrea L Cheville et al. J Pain Symptom Manage. 2011 Aug.

Abstract

Context: Aggregates of concurrent symptoms, known as symptom clusters (SxCls), have been described in predominantly cross-sectional samples of lung cancer (LC) patients undergoing treatment.

Objectives: The objective of this study was to delineate SxCls in LC survivors up to five years after diagnosis, investigate their stability over time, and identify determinants of SxCl development and resolution.

Methods: A sensitivity approach involving multiple exploratory and confirmatory analyses was applied to an eight-year prospective cohort study that annually assessed 2405 patients with LC for symptom burden with the Lung Cancer Symptom Scale and Linear Analogue Self-Assessment.

Results: A single robust SxCl of fatigue, cough, and dyspnea was identified in 14.6%, 12.9%, 14.1%, 14.6%, and 15.4% of participants at Years 1-5 after diagnosis, respectively. Participants with the SxCl (SxCl (+)) were more likely to die than those without it; but this tendency diminished over time. SxCl persistence varied, with ≥40% of surviving patients annually transitioning to or from the SxCl(+) state until Year 4, after which the SxCl became increasingly stable. The SxCl was more likely to develop among male survivors who underwent surgery, received radiation, and were current smokers.

Conclusion: A single SxCl comprising dyspnea, fatigue, and cough has a stable prevalence among LC survivors up to five years after diagnosis but is not stable among individuals. Initially, after diagnosis, the SxCl is associated with a greater risk of death; however, after Year 2, the SxCl becomes increasingly stable and provides a marker for parenchymal lung injury.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Dendrogram of <1 cluster analysis.
Figure 2
Figure 2
Cumulative scree plots for factor analyses of data from years <1 through 5.
Figure 3
Figure 3
Latent variable structure derived from the modeled data.
Figure 4
Figure 4
Frequencies of transitions between symptom cluster-defined states and death over the first five years following lung cancer diagnosis. SxCl = symptom cluster.
Figure 5
Figure 5
Alterations over time first five years following lung cancer diagnosis in the probability of dying and transitioning between symptom cluster-defined states. SxCl = symptom cluster.

References

    1. Pud D, Ben Ami S, Cooper BA, et al. The symptom experience of oncology outpatients has a different impact on quality-of-life outcomes. J Pain Symptom Manage. 2008;35(2):162–170. - PubMed
    1. Miaskowski C, Aouizerat BE, Dodd M, Cooper B. Conceptual issues in symptom clusters research and their implications for quality-of-life assessment in patients with cancer. J Natl Cancer Inst Monogr. 2007;37:39–46. - PubMed
    1. Miaskowski C, Cooper BA, Paul SM, et al. Subgroups of patients with cancer with different symptom experiences and quality-of-life outcomes: a cluster analysis. Oncol Nurs Forum. 2006;33(5):E79–89. - PubMed
    1. Gift AG. Symptom clusters related to specific cancers. Semin Oncol Nurs. 2007;23(2):136–141. - PubMed
    1. Hopwood P, Stephens RJ. Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party. Br J Cancer. 1995;71(3):633–636. - PMC - PubMed

Publication types